Crossmark

Re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48–55

Crossref DOI link: https://doi.org/10.1016/j.eururo.2017.05.027

Published Print: 2017-11

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Eriksson, Pontus

Sjödahl, Gottfrid

Liedberg, Fredrik http://orcid.org/0000-0001-8193-0370
License Information

Text and Data Mining valid from 2017-11-01
More Information

This article is maintained by: Elsevier

Article Title: Re: Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48–55

Journal Title: European Urology

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.eururo.2017.05.027

Content Type: simple-article

Copyright: © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Document is current

Any future updates will be listed below